文献速递胸部肿瘤

劳拉替尼在经二代ALK TKI治疗的ALK阳性NSCLC中的颅内与颅外疗效

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
PubMed 文献 · Ann Oncol · 2021-02-24

本研究基于II期研究(NCT01970865)扩展队列,评估劳拉替尼在经≥1种二代ALK TKI±化疗后进展的ALK阳性晚期NSCLC患者的整体、颅内和颅外抗肿瘤活性。结果显示,在139例患者中,整体ORR为39.6%,颅内ORR为56.1%,颅外ORR为36.7%,中位PFS为6.6个月,中位OS为20.7个月。结论认为劳拉替尼在二代ALK TKI治疗后具有临床意义的颅内和颅外抗肿瘤活性,且颅内ORR高于颅外ORR,尤其在治疗线数较少的患者中。

要点

  • 劳拉替尼在经二代ALK TKI治疗失败后仍显示颅内和颅外抗肿瘤活性。
  • 颅内ORR(56.1%)高于颅外ORR(36.7%),提示对脑转移有效。
  • 治疗线数较少者(仅一种二代ALK TKI)颅内ORR更高(66.7%)。

核心结论

  • 劳拉替尼在二代ALK TKI治疗后进展的ALK阳性NSCLC中具有临床意义的颅内和颅外抗肿瘤活性。
  • 颅内ORR高于颅外ORR,尤其在既往治疗线数较少的患者中。

研究设计与样本

  • 正在进行的II期研究(NCT01970865)的扩展队列分析。
  • 纳入139例经≥1种二代ALK TKI±化疗的ALK阳性晚期NSCLC患者,按治疗史分为EXP3B(一种二代ALK TKI,28例)、EXP4(两种ALK TKI,65例)、EXP5(三种ALK TKI,46例)。
  • 整体、颅内和颅外抗肿瘤活性分别按改良RECIST v1.1独立评估。

主要发现

  • 在EXP3B-5总体人群中,ORR为39.6%(95%CI 31.4-48.2),颅内ORR为56.1%(95%CI 42.4-69.3),颅外ORR为36.7%(95%CI 28.7-45.3)。
  • 中位DOR为9.6个月(95%CI 5.6-16.7),颅内DOR为12.4个月(95%CI 6.0-37.1),颅外DOR为9.7个月(95%CI 6.1-33.3)。
  • 中位PFS为6.6个月(95%CI 5.4-7.4),中位OS为20.7个月(95%CI 16.1-30.3)。
  • EXP3B亚组ORR为42.9%(95%CI 24.5-62.8),颅内ORR为66.7%(95%CI 29.9-92.5),颅外ORR为32.1%(95%CI 15.9-52.4)。
  • EXP4和EXP5合并ORR为38.7%(95%CI 29.6-48.5),颅内ORR为54.2%(95%CI 39.2-68.6),颅外ORR为37.8%(95%CI 28.8-47.5)。

临床怎么用

  • 对于经二代ALK TKI治疗后进展的ALK阳性NSCLC患者,劳拉替尼可作为后续治疗选择,尤其关注颅内病灶控制。
  • 治疗线数较少的患者可能从劳拉替尼中获得更高的颅内缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This study assessed the overall, intracranial, and extracranial efficacy of lorlatinib in ALK-positive NSCLC that progressed on second-generation ALK TKIs. PATIENTS AND METHODS: In the ongoing phase II study (NCT01970865), patients with ALK-positive advanced NSCLC treated with ≥1 prior second-generation ALK TKI ± chemotherapy were enrolled in expansion cohorts (EXP) based on treatment history. Overall, intracranial and extracranial antitumor activity were assessed independently per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. RESULTS: Of the 139 patients with ≥1 prior second-generation ALK TKI (EXP3B-5), 28 received one prior second-generation ALK TKI (EXP3B), 65 two prior ALK TKIs (EXP4), and 46 three prior ALK TKIs (EXP5). In EXP3B-5, the objective response rate (ORR) [95% confidence intervals] was 39.6% (31.4-48.2), intracranial ORR (IC-ORR) was 56.1% (42.4-69.3), extracranial ORR (EC-ORR) was 36.7% (28.7-45.3), median duration of response (DOR) was 9.6 months [5.6-16.7; IC-DOR, 12.4 (6.0-37.1); EC-DOR, 9.7 (6.1-33.3)], median progression-free survival was 6.6 (5.4-7.4) months, and median overall survival was 20.7 months (16.1-30.3). In EXP3B, the ORR was 42.9% (24.5-62.8), the IC-ORR was 66.7% (29.9-92.5), and the EC-ORR was 32.1% (15.9-52.4). In EXP4 and EXP5, the ORR was 38.7% (29.6-48.5), the IC-ORR was 54.2% (39.2-68.6), and the EC-ORR was 37.8% (28.8-47.5). CONCLUSIONS: Lorlatinib had clinically meaningful intracranial and extracranial antitumor activity in the post-second-generation ALK TKI setting, with elevated intracranial versus extracranial ORR, particularly in patients with fewer lines of therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021. PMID: 33639216. doi:10.1016/j.annonc.2021.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。